## 



## 

|**Contents**<br>**Vear ended 31 December 2025**||
|---|---|
||**Page**|
|Legal and administrative information|2|
|Summary|3|
|Founder's Statement|5|
|Report of the Trustees|6|
|Report of the Independent Auditors|14|
|Consolidated Statement of Financial Activities|17|
|Balance Sheets|18|
|Consolidated Cash Flow Statement|19|
|Notes forming part of the Financial Statements|20|






## 

## 

## 

## 




## 

## 



## 

## 

## 



## 



## 

## 



## 

## 



## 

## 



## 




## 

## 

## 

## 

## 



## 

## 

## 

## 





## 

## 

## 

## 

## 



## 

## 

## 

## 

## 




# 26/10/2026 



|**Notes**<br>**Income**<br>Income from<br>donations<br>2<br>Income from<br>investments<br>**Total**<br>**Expenditure**<br>Charitable<br>activities<br>3<br>Raising funds<br>4<br>**Total**<br>**Net movement**<br>in**funds**<br>**Transfer of**<br>**funds**<br>8<br>**Funds brought**<br>**forward**<br>**Funds carried**<br>**forward**|**Unrestricted**<br>£<br>**218,750**<br>**1,320**<br>**220,070**<br>**116,790**<br>**70,870**<br>**187,660**<br>**32,410**<br>**235,377**<br>**267,787**|**Restricted**<br>£<br>**3,264,413**<br>**63,893**<br>**3,328,306**<br>**1,091,508**<br>**13,072**<br>**1,104,580**<br>**2,223,726**<br>**4,890,175**<br>**7,113,901**|**2025**<br>**Total**<br>£<br>**3,483,163**<br>**65,213**<br>**3,548,376**<br>**1,208,298**<br>**83,942**<br>**1,292,240**<br>**2,256,136**<br>**5,125,552**<br>**7,381,688**|Unrestricted<br>£<br>257,450<br>257,450<br>92,494<br>129,499<br>221,993<br>35,457<br>199,920<br>235,377|Restricted<br>£<br>4,550,018<br>43,295<br>4,593,313<br>1,155,172<br>33,789<br>1,188,961<br>3,404,352<br>1,485,823<br>4,890,175|2024<br>Total<br>£<br>4,807,468<br>43,295|
|---|---|---|---|---|---|---|
|||||||4,850,763|
|||||||1,247,666<br>163,288|
|||||||1,410,954|
|||||||3,439,809<br>1,685,743|
|||||||5,125,552|





## 

|**Notes**<br>**Fixed assets**<br>Investments<br>5<br>**Current assets**<br>Cash at bank<br>Other debtors<br>6<br>Current asset investments<br>7<br>Creditors:<br>Amounts falling due within one year<br>8<br>**Net current assets**<br>**Total assets less current liabilities**<br>Creditors: amounts falling due after<br>more than one year<br>9<br>**Total net assets**<br>**The funds of the charity**<br>Unrestricted income funds<br>Restricted income funds<br>**Total funds**|**Group**<br>**2025**<br>2024<br>£<br>£<br>**899,841**<br>317,752<br>**4,027,086**<br>1,852,797<br>**90,389**<br>2,119,345<br>**4,500,000**<br>2,500,000<br>**8,617,475**<br>6,472,142<br>**(1,668,905)**<br>(1,169,204)<br>**6,948,570**<br>5,302,938<br>**7,848,411**<br>5,620,690<br>**(466,723)**<br>(495,138)<br>**7,381,688**<br>5,125,552<br>**267,787**<br>235,377<br>**7,113,901**<br>4,890,175<br>**7,381,688**<br>5,125,552|**Charity**<br>**2025**<br>2024<br>£<br>£<br>**899,941**<br>317,852<br>**3,908,795**<br>1,675,292<br>**90,389**<br>2,119,345<br>**4,500,000**<br>2,500,000<br>**8,499,184**<br>6,294,637<br>**(1,550,714)**<br>(991,799)<br>**6,948,470**<br>5,302,838<br>**7,848,411**<br>5,620,690<br>**(466,723)**<br>(495,138)<br>**7,381,688**<br>5,125,552<br>**299,484**<br>267,074<br>**7,082,204**<br>4,858,478<br>**7,381,688**<br>5,125,552|**Charity**<br>**2025**<br>2024<br>£<br>£<br>**899,941**<br>317,852<br>**3,908,795**<br>1,675,292<br>**90,389**<br>2,119,345<br>**4,500,000**<br>2,500,000<br>**8,499,184**<br>6,294,637<br>**(1,550,714)**<br>(991,799)<br>**6,948,470**<br>5,302,838<br>**7,848,411**<br>5,620,690<br>**(466,723)**<br>(495,138)<br>**7,381,688**<br>5,125,552<br>**299,484**<br>267,074<br>**7,082,204**<br>4,858,478<br>**7,381,688**<br>5,125,552|
|---|---|---|---|
||||1,675,292<br>2,119,345<br>2,500,000|
||||6,294,637<br>(991,799)|
||||5,302,838|
||||5,620,690<br>(495,138)|
||||5,125,552|
||||267,074<br>4,858,478|
||||5,125,552|







|**2025**<br>£<br>**Net movement of funds from operating activities**<br>**2,256,136**<br>Impairment of fixed asset investments<br>**100,000**<br>Purchase of fixed asset investments<br>**(682,089)**<br>Increase in debtors/ investments (Notes 6 and 7)<br>**28,956**<br>Increase in creditors (Notes 8 and 9)<br>**471,287**<br>**Net cash inflow from operations**<br>**2,174,289**<br>Cash at the beginning of the year<br>**1,852,797**<br>Cash at the end of the year<br>**4,027,086**|2024<br>£<br>3,439,809<br>100,000<br>(299,325)<br>(2,963,898)<br>233,702|
|---|---|
||510,288<br>1,342,509|
||1,852,797|





## 

## 

## 

## 

## 

## 



## 

## 

## 

## 

## 

## 

## 



|3.<br>**Charitable activities**<br>**Research projects:**<br>University of Minnesota - Nanocol<br>Gene Editing Trial - UC3 Madrid<br>Base & Prime Editing strategies for RDEB<br>University of Colorado - Spray on Skin<br>EB Cancer Therapy<br>Oligo<br>EB Graft<br>lnserm - SIRNA<br>JEB Airway Disease<br>Decorin<br>Bespoke Therapy<br>mRNA-based base editing<br>Chemoprevention<br>James Lind Alliance<br>Nanocure<br>**Other costs:**<br>Impairment losses<br>**Support costs:**<br>Administration costs<br>Bank charges<br>Audit<br>Charitable Events - restricted<br>Research Events - restricted<br>Insurance<br>**4.**<br>**Raising funds**<br>Fund raising and marketing<br>Fundraising administration costs<br>**2025**<br>£<br>**(26)**<br>**(1,525)**<br>**38,166**<br>**235**<br>**326,211**<br>**214,843**<br>**10,000**<br>**358,656**<br>**100,000**<br>**102,206**<br>**272**<br>**13,035**<br>**44,561**<br>**387**<br>**1,277**<br>**1,208,298**<br>**2025**<br>£<br>**36,197**<br>**47,745**<br>**83,942**|2024<br>£<br>38,802<br>350,730<br>(558,897)<br>147,033<br>638,664<br>66,767<br>80,000<br>16,951<br>267,198<br>100,000<br>80,490<br>274<br>10,532<br>6,625<br>1,300<br>1,197<br>1,247,666|
|---|---|
||2024<br>£<br>34,518<br>128,770<br>163,288|





## 

|**Fixed asset investments**-**held by Group and Charity**<br>**Social investments**-**unlisted**<br>Cost at 1 January 2025<br>Additions<br>Cost at 31 December 2025<br>**Impairment**<br>Charge for the year<br>**Net book value**<br>At 31 December 2025<br>At 31 December 2024<br>**Shares in Group undertakings held by Charity**<br>Cost at 1 January 2025<br>Cost at 31 December 2025<br>**Net book value**<br>Cost at 31 December 2024|**2025**<br>£<br>**317,752**<br>**682,089**<br>**999,841**<br>**(100,000)**<br>**899,841**<br>**317,752**<br>**2025**<br>£<br>**100**<br>**100**<br>**100**|2024<br>£<br>118,427<br>299,325<br>417,752<br>(100,000)|
|---|---|---|
|||317,752<br>118,427|
|||2024<br>£<br>100<br>100|
|||100|



## 

## 



|**Debtors**||**Group**||**Charity**|
|---|---|---|---|---|
||**2025**|2024|**2025**|2024|
||£|£|£|£|
|Other debtors|**90,389**|2,119,345|**90,389**|2,119,345|



## 

|**Current Asset investments**<br>Treasury Bonds<br>**Creditors: amounts falling due within one**<br>**year**<br>Trade creditors<br>Amounts owed to intercompany<br>Unpaid share capital<br>Committed grants|**Group**<br>**2025**<br>2024<br>£<br>£<br>**4,500,000**<br>2,500,000<br>**Group**<br>**2025**<br>2024<br>£<br>£<br>**240,613**<br>258,473<br>**1,428,292**<br>910,731<br>**1,668,905**<br>1,169,204|**Charity**<br>**2025**<br>2024<br>£<br>£<br>**4,500,000**<br>2,500,000<br>**Charity**<br>**2025**<br>2024<br>£<br>£<br>**18,192**<br>15,005<br>**104,130**<br>65,963<br>**100**<br>100<br>**1,428,292**<br>910,731<br>**1,550,714**<br>991,799|2024<br>£<br>2,500,000|
|---|---|---|---|
||||991,799|



## 

## 

## 

## 

|**Group**<br>**2025**<br>**2024**<br>£<br>£<br>466,723<br>495,138<br>**466,723**<br>495,138|**Charity**<br>**2025**<br>**2024**<br>£<br>£<br>466,723<br>495,138<br>**466,723**<br>495,138|**Charity**<br>**2025**<br>**2024**<br>£<br>£<br>466,723<br>495,138<br>**466,723**<br>495,138|
|---|---|---|
|||495,138|





|**10.**<br>**Fund balances**- **Current year**<br>Balance brought forward<br>Income<br>Expenditure<br>Inter fund transfer<br>Balance carried forward<br>**Represented by:**<br>Fixed assets<br>Cash at bank<br>Other net assets/liabilities<br>**Brought**<br>**Current year**<br>**Forward**<br>£<br>**Research Projects**<br>Therapy for RDEBsec<br>50,000<br>Gene Editing Trial<br>EB Cancer Therapy<br>Decorin<br>SIRNA<br>37,103<br>mRNA-based base<br>editing<br>James Lind Alliance<br>Nanocure<br>**Social Investments**<br>Nonsense Therapeutics<br>100,000<br>Healome<br>Eliksa<br>Replay<br>FIBRX Derm<br>Other Social<br>Investments<br>118,427<br>Nova Anchora<br>99,325<br>**Other Research Funds**<br>Unassigned Research<br>Funds<br>557,360<br>**Other Restricted Funds**<br>ABE Fund<br>424,756<br>Translational Fund<br>3,472,549<br>Ebolution Fund<br>Funds for Fundraiser<br>5,280<br>Research Events<br>Children's Fund<br>25,375<br>4,890,175|**Income**<br>£<br>103,908<br>200,000<br>100,000<br>114,632<br>74,890<br>192,568<br>283,859<br>304,073<br>1,525,411<br>378,165<br>800<br>50,000<br>3,328,306|**Expenditure**<br>£<br>(214,843)<br>26<br>1,525<br>(235)<br>(326,211)<br>(10,000)<br>(358,656)<br>(13,072)<br>(38,166)<br>(387)<br>(44,561)<br>(1,004,580)|**Unrestricted**<br>**Funds**<br>£<br>235,377<br>220,070<br>(187,660)<br>267,787<br>267,787<br>267,787<br>**Gains/Losses**<br>£<br>(100,000)<br>(100,000)|**Restricted**<br>**Funds**<br>£<br>4,890,175<br>3,328,306<br>(1,104,580)<br>7,113,901<br>899,841<br>3,759,299<br>2,454,761<br>7,113,901<br>**Transfers**<br>£<br>164,843<br>(26)<br>(1,525)<br>235<br>222,303<br>10,000<br>358,656<br>(754,486)|**Total**<br>£<br>5,125,552<br>3,548,376<br>(1,292,240)<br>7,381,688<br>899,841<br>4,027,086<br>2,454,761<br>7,381,688<br>**Carried**<br>**Forward**<br>£<br>**37,103**<br>**200,000**<br>**100,000**<br>**114,632**<br>**74,890**<br>**192,568**<br>**118,427**<br>**99,325**<br>**86,733**<br>**715,757**<br>**4,959,794**<br>**378,165**<br>**5,280**<br>**413**<br>**30,814**<br>**7,113,901**|**Total**<br>£<br>5,125,552<br>3,548,376<br>(1,292,240)<br>7,381,688<br>899,841<br>4,027,086<br>2,454,761<br>7,381,688<br>**Carried**<br>**Forward**<br>£<br>**37,103**<br>**200,000**<br>**100,000**<br>**114,632**<br>**74,890**<br>**192,568**<br>**118,427**<br>**99,325**<br>**86,733**<br>**715,757**<br>**4,959,794**<br>**378,165**<br>**5,280**<br>**413**<br>**30,814**<br>**7,113,901**|
|---|---|---|---|---|---|---|
||||||||
|||||||**7,113,901**|





|**10**<br>**Fund balances (Continued)**<br>**Previous Year**<br>Balance brought forward<br>Income<br>Expenditure<br>Inter fund transfer<br>Balance carried forward<br>**Represented by:**<br>Fixed assets<br>Cash at bank<br>Other net assets/liabilities<br>**Brought**<br>**Previous year**<br>**Forward**<br>£<br>**Research Projects**<br>Therapy for RDEB~~sec~~<br>50,000<br>EB Graft<br>Gene Editing Trial<br>Spray on Skin<br>Base & prime editing<br>strategies for RDEB<br>EB Cancer Therapy<br>Bespoke Therapy<br>JEB Airway Disease<br>Decorin<br>SIRNA<br>**Social Investments**<br>Nonsense<br>Therapeutics (ABE<br>Fund)<br>Other Social<br>Investments<br>118,427<br>Nova Anchora<br>**Other Research Funds**<br>Unassigned Research<br>Funds<br>198,300<br>**Other Restricted**<br>**Funds**<br>ABE Fund<br>26,818<br>Translational Fund<br>1,086,078<br>Funds for Fundraiser<br>6,200<br>Research Events<br>Children's Fund<br>1,485,823|**Income**<br>£<br>37,103<br>108,631<br>37,103<br>200,000<br>99,325<br>621,910<br>412,807<br>3,025,134<br>1,300<br>50,000<br>4,593,313|**Expenditure**<br>£<br>(66,767)<br>(38,802)<br>558,897<br>(350,730)<br>(147,033)<br>(267,198)<br>(80,000)<br>(16,951)<br>(14,869)<br>(638,663)<br>(920)<br>(1,300)<br>(24,625)<br>(1,088,961)|**Unrestricted**<br>**Funds**<br>£<br>199,920<br>257,450<br>(221,993)<br>235,377<br>235,377<br>235,377<br>**Gains/Losses**<br>£<br>(100,000)<br>(100,000)|**Restricted**<br>**Funds**<br>£<br>1,485,823<br>4,593,313<br>(1,188,961)<br>4,890,175<br>317,752<br>1,617,420<br>2,955,003<br>4,890,175<br>**Transfers**<br>£<br>66,767<br>38,802<br>(596,000)<br>242,099<br>147,033<br>267,198<br>80,000<br>16,951<br>(262,850)|**Total**<br>£<br>1,685,743<br>4,850,763<br>(1,410,954)<br>5,125,552<br>317,752<br>1,852,797<br>2,955,003<br>5,125,552<br>**Carried**<br>**Forward**<br>£<br>**50,000**<br>**37,103**<br>**100,000**<br>**118,427**<br>**99,325**<br>**557,360**<br>**424,756**<br>**3,472,549**<br>**5,280**<br>**25,375**<br>**4,890,175**|
|---|---|---|---|---|---|
|Therapy for RDEB~~sec~~<br>EB Graft<br>Gene Editing Trial<br>Spray on Skin<br>Base & prime editing<br>strategies for RDEB<br>EB Cancer Therapy<br>Bespoke Therapy<br>JEB Airway Disease<br>Decorin<br>SIRNA<br>**Social Investments**<br>Nonsense<br>Therapeutics (ABE<br>Fund)<br>Other Social<br>Investments<br>Nova Anchora<br>**Other Research Funds**<br>Unassigned Research<br>Funds<br>**Other Restricted**<br>**Funds**<br>ABE Fund<br>Translational Fund<br>Funds for Fundraiser<br>Research Events<br>Children's Fund||||||





## 

## 

## 

## 

## 

